28 May, 14:34 - Indian

SENSEX 81420.76 (-0.16)

Nifty 50 24771.7 (-0.22)

Nifty Bank 55349.05 (-0.01)

Nifty IT 37528.75 (0.07)

Nifty Midcap 100 57241.2 (0.15)

Nifty Next 50 67097.45 (-0.14)

Nifty Pharma 21393.25 (-0.61)

Nifty Smallcap 100 17779.7 (0.31)

28 May, 14:34 - Global

NIKKEI 225 37722.4 (0.00)

HANG SENG 23258.31 (-0.53)

S&P 5936.5 (-0.16)


Corporate News

You are Here : Home > News > Corporate News >

(26 Jul 2024, 09:42)

Sun Pharma gets US FDA nod for alopecia areata treatment drug LEQSELVI

Sun Pharmaceutical Industries said that it has received approval from the U.S. Food and Drug Administration (US FDA) for LEQSELVI (deuruxolitinib), an oral JAK Inhibitor for the treatment of severe alopecia areata.


Alopecia areata is a common autoimmune disease in which hair loss is thought to occur due to the collapse of immune privilege, leading to the immune system targeting the hair follicles and causing sudden hair loss on the scalp, face and sometimes other areas of the body.

Alopecia areata affects around 700,000 people in the United States, and 300,000 have severe alopecia areata. Alopecia often leads patients to self-treat before seeking professional help, driven by dissatisfaction with the slow progress of existing treatments.

As a JAK inhibitor, LEQSELVI interrupts the pathways thought to contribute to hair loss in severe alopecia areata.

Abhay Gandhi, CEO, North America Business, Sun Pharma, said: “LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians. Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.”

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company.

The pharma major’s consolidated net profit jumped 33.77% to Rs 2,654.58 crore on 10.14% growth in revenue from operations to Rs to Rs 11,813.33 crore in Q4 FY24 over Q4 FY23.

The scrip rose 0.47% to currently trade at Rs 1672.95 on the BSE.


More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +